Innoviva (INVA) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Innoviva (INVA) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, gaining 22.4% versus a gain of 3.5%. Over five years, INVA leads with a +26.8% price change compared with -8.4% for SNDX. Innoviva is the larger company by market cap ($1.51 billion vs $1.49 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INVA | SNDX |
|---|---|---|
| Share price | $20.90 | $16.70 |
| Market cap | $1.51B | $1.49B |
| 1-day change | -0.76% | -1.97% |
| YTD return | +5.35% | -18.94% |
| 1-year return | +22.44% | +3.53% |
| 5-year return | +26.79% | -8.39% |
| P/E ratio (TTM) | 4.88 | — |
| Forward P/E | 9.46 | — |
| EPS (TTM) | $4.28 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.15 | $25.59 |
| 52-week low | $16.52 | $12.99 |
| Distance from 52-week high | -16.90% | -34.76% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +67.46% | +124.92% |
| Average volume | 819.96K | 1.54M |
| Shares outstanding | 72.25M | 89.30M |
| Employees | 159 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INVA has outperformed SNDX by 18.9 percentage points over the past year.
About Innoviva
INVA stock →Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 159 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
INVA vs SNDX FAQ
Which is bigger, Innoviva or Syndax Pharmaceuticals?
Innoviva (INVA) is larger, with a market capitalization of $1.51B compared with $1.49B for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, INVA or SNDX?
INVA returned +22.44% over the past 12 months, compared with +3.53% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Innoviva and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.